Healthy Volunteers Clinical Trial
— IG-DESSERTOfficial title:
Determination of the Glycemic Index of Pastry. A Randomized Study on Healthy Volunteers.
Verified date | March 2022 |
Source | Institut Pasteur de Lille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In the early 1980s and following the first publications by Jenkins et al., The notion of glycemic index (GI) appeared with the aim of classifying the different sources of carbohydrates in our diet according to their effect on the post-prandial glycemic response. Since these years, many studies have been designed to determine the usefulness of the glycemic index and indicate that a low glycemic index for a food, a dish, a meal or a diet is associated with a decreased risk of metabolic pathologies (diabetes, hypertriglyceridemia), degenerative (cardiovascular diseases) or overload (obesity). This justifies the interest in favoring foods with a low glycemic index in healthy subjects. A review confirmed the mechanistic link between postprandial blood sugar and the variability of blood sugar, making it possible, on the one hand, to maintain good glucose homeostasis and, on the other hand, to prevent pathologies such as obesity, diabetes and cardio-vascular diseases. The EFSA also considers that reducing the increase in blood sugar in the post-meal phase can be considered a physiological benefit, especially in subjects with glucose intolerance. Post-meal blood sugar depends on many factors including the glycemic index of foods eaten during the meal. Knowing the glycemic index of foods is therefore very useful. Mademoiselle Dessert offers pastries with a low glycemic index. The objective of this study is thus to determine the glycemic index of 6 pastries in order to inform consumers on these pastries glycemic index.
Status | Completed |
Enrollment | 10 |
Est. completion date | July 6, 2021 |
Est. primary completion date | July 6, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Man or woman ; - Aged 18 to 65 (limits included); - Having a body mass index (BMI) between 18 and 30 kg / m² (limits included); - Agreeing to maintain their lifestyle (sport and diet) for the duration of the study; - Agreeing not to smoke on the morning of each visit (before and during the visit). Exclusion Criteria: - Fasting blood glucose = 6.1 mmol / L (or 1.10 g / L); - Fasting triglycerides ? 2 g / L; - Hyperinsulinemia (20 mIU / L) or history of insulinoma; - Elevation of transaminases beyond 2x the upper limit; - Subject presenting episodes of functional post-meal hypoglycaemia; - Diabetic subject whether or not treated; - Subject suffering from a severe eating disorder (anorexia, bulimia, binge eating); - Subject presenting an immunodeficiency or any other serious pathology (cancer, hemopathy); - Subject with a history of hypercholesterolemia and high blood pressure; - Subject with renal failure; - Subject with an allergy / intolerance to one of the constituents of the products under study; - Subject with an intestinal pathology likely to modify digestion or absorption (Crohn's disease, etc.); - Subject consuming more than 3 glasses of alcohol per day for men and more than 2 glasses per day for women; - Subject not having a stable weight for the last 3 months (± 5%); - Woman pregnant or planning to be during the study period, breastfeeding woman. |
Country | Name | City | State |
---|---|---|---|
France | NutrInvest - Institut Pasteur de Lille | Lille | Nord |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur de Lille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
0 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
15 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
30 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
45 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
60 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
90 min | |
Primary | Glycemia: 7-point kinetics | Blood glucose kinetics over 2 hours, performed from 7 blood samples and at 7 different times: T = 0, T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 min, on each test product and on the reference product (glucose).
Visits V1 to V8 |
120 min | |
Secondary | Peak blood sugar (Cmax-Gly) | For each product and from the glycemia and insulinemia dosage curves: peak blood sugar (Cmax-Gly).
Visits V1 to V8 |
0, 15, 30, 45, 60, 90 and 120 min | |
Secondary | The time to onset of the blood sugar peak (Tmax-Gly) | For each product and from the glycemia and insulinemia dosage curves: the time to onset of the blood sugar peak (Tmax-Gly). Visits V1 to V8 | 0, 15, 30, 45, 60, 90 and 120 min | |
Secondary | Insulin index | For each product and from the glycemia and insulinemia dosage curves: insulin index Visits V1 to V8 | 0, 15, 30, 45, 60, 90 and 120 min | |
Secondary | Peak insulinemia (Cmax-Ins) | For each product and from the glycemia and insulinemia dosage curves: peak insulinemia (Cmax-Ins).
Visits V1 to V8 |
0, 15, 30, 45, 60, 90 and 120 min | |
Secondary | The time to onset of peak insulinemia (Tmax-Ins) | For each product and from the glycemia and insulinemia dosage curves: the time to onset of peak insulinemia (Tmax-Ins). Visits V1 to V8 | 0, 15, 30, 45, 60, 90 and 120 min |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |